Terms: = Breast cancer AND TOP2A, TOP2, TP2A
297 results:
1. The correlation study between top2a gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH; Yu J; Huang MY; Mo YM
Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
[TBL] [Abstract] [Full Text] [Related]
2. Anthracyclines induce cardiotoxicity through a shared gene expression response signature.
Matthews ER; Johnson OD; Horn KJ; Gutiérrez JA; Powell SR; Ward MC
PLoS Genet; 2024 Feb; 20(2):e1011164. PubMed ID: 38416769
[TBL] [Abstract] [Full Text] [Related]
3. Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
Rakhshaninejad M; Fathian M; Shirkoohi R; Barzinpour F; Gandomi AH
BMC Bioinformatics; 2024 Jan; 25(1):33. PubMed ID: 38253993
[TBL] [Abstract] [Full Text] [Related]
4. Effectivity of Bromocriptine Administration Towards Prolactin Positive breast cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review.
Permana MY; Sarwanti S; Fauziah S
Acta Med Indones; 2023 Oct; 55(4):465-474. PubMed ID: 38213041
[TBL] [Abstract] [Full Text] [Related]
5. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating top2a.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
6. Copy number variants landscape of multiple cancers and clinical applications based on NGS gene panel.
Yan K; Niu L; Wu B; He C; Deng L; Chen C; Lan Z; Lin C; Kuang W; Lin H; Zou J; Zhang W; Luo Z
Ann Med; 2023; 55(2):2280708. PubMed ID: 37967237
[TBL] [Abstract] [Full Text] [Related]
7. Network based approach to identify interactions between Type 2 diabetes and cancer comorbidities.
Nayan SI; Rahman MH; Hasan MM; Raj SMRH; Almoyad MAA; Liò P; Moni MA
Life Sci; 2023 Dec; 335():122244. PubMed ID: 37949208
[TBL] [Abstract] [Full Text] [Related]
8. [Risk factors for cancer-related cognitive impairment in breast and colorectal cancer patients who undergo chemotherapy].
Iranzo P; Callejo A; Arbej J; Menao S; Isla D; Andrés R
An Sist Sanit Navar; 2023 Aug; 46(2):. PubMed ID: 37594060
[TBL] [Abstract] [Full Text] [Related]
9. Bioinformatics analysis to identify breast cancer-related potential targets and candidate small molecule drugs.
Hong H; Chen H; Zhao J; Qin L; Li H; Huo H; Shi S
Mutat Res; 2023; 827():111830. PubMed ID: 37437506
[TBL] [Abstract] [Full Text] [Related]
10. Proteomic Dynamics of breast cancer Cell Lines Identifies Potential Therapeutic Protein Targets.
Sun R; Ge W; Zhu Y; Sayad A; Luna A; Lyu M; Liang S; Tobalina L; Rajapakse VN; Yu C; Zhang H; Fang J; Wu F; Xie H; Saez-Rodriguez J; Ying H; Reinhold WC; Sander C; Pommier Y; Neel BG; Aebersold R; Guo T
Mol Cell Proteomics; 2023 Aug; 22(8):100602. PubMed ID: 37343696
[TBL] [Abstract] [Full Text] [Related]
11. O-GlcNAcylation promotes topoisomerase IIα catalytic activity in breast cancer chemoresistance.
Liu Y; Yu K; Zhang K; Niu M; Chen Q; Liu Y; Wang L; Zhang N; Li W; Zhong X; Li G; Wu S; Zhang J; Liu Y
EMBO Rep; 2023 Jul; 24(7):e56458. PubMed ID: 37249035
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer.
Ren X; Song Y; Pang J; Chen L; Zhou L; Liang Z; Wu H
Front Immunol; 2023; 14():1137561. PubMed ID: 37090736
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low breast cancers: A Retrospective, Multicenter Cohort Study.
Yang L; Liu Y; Han D; Fu S; Guo S; Bao L; Shi Y; Huang R; Wan H; Li W; Wang Z; Zhou X; Chen G; Liu Y; Ye F
Ann Surg Oncol; 2023 Sep; 30(9):5653-5662. PubMed ID: 37000356
[TBL] [Abstract] [Full Text] [Related]
14. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract] [Full Text] [Related]
15. Identification and validation of eight estrogen-related genes for predicting prognosis of papillary thyroid cancer.
Zeng Y; Ma W; Li L; Zhuang G; Luo G; Zhou H; Hao W; Liu Y; Guo F; Tian M; Ruan X; Gao M; Zheng X
Aging (Albany NY); 2023 Mar; 15(5):1668-1684. PubMed ID: 36917092
[TBL] [Abstract] [Full Text] [Related]
16. Exploring the causality and pathogenesis of systemic lupus erythematosus in breast cancer based on Mendelian randomization and transcriptome data analyses.
Li W; Wang R; Wang W
Front Immunol; 2022; 13():1029884. PubMed ID: 36726984
[TBL] [Abstract] [Full Text] [Related]
17. top2a Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor Clinical Outcome?
Solhusløkk Höse K; Stenman A; Svahn F; Larsson C; Juhlin CC
Endocr Pathol; 2023 Mar; 34(1):129-141. PubMed ID: 36656469
[TBL] [Abstract] [Full Text] [Related]
18. ATM suppresses c-Myc overexpression in the mammary epithelium in response to estrogen.
Najnin RA; Al Mahmud MR; Rahman MM; Takeda S; Sasanuma H; Tanaka H; Murakawa Y; Shimizu N; Akter S; Takagi M; Sunada T; Akamatsu S; He G; Itou J; Toi M; Miyaji M; Tsutsui KM; Keeney S; Yamada S
Cell Rep; 2023 Jan; 42(1):111909. PubMed ID: 36640339
[TBL] [Abstract] [Full Text] [Related]
19. Verteporfin-loaded microparticles for radiosensitization of preclinical lung and breast metastatic spine cancer.
Akinduro OO; Suarez-Meade P; Roberts M; Tzeng SY; Sarabia-Estrada R; Schiapparelli P; Norton ES; Gokaslan ZL; Anastasiadis PZ; Guerrero-Cázares H; Green JJ; Quiñones-Hinojosa A
J Neurosurg Spine; 2023 Apr; 38(4):481-493. PubMed ID: 36585863
[TBL] [Abstract] [Full Text] [Related]
20. A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
Xu H; Hurley LH
Bioorg Med Chem Lett; 2022 Dec; 77():129016. PubMed ID: 36195286
[TBL] [Abstract] [Full Text] [Related]
[Next]
